Galena Biopharma Inc  

(Public, NASDAQ:GALE)   Watch this stock  
Find more results for GALE
0.630
-0.030 (-4.58%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.62 - 0.68
52 week 0.59 - 2.39
Open 0.67
Vol / Avg. 1.16M/2.11M
Mkt cap 119.92M
P/E     -
Div/yield     -
EPS -0.24
Shares 181.67M
Beta 1.21
Inst. own 15%
Mar 14, 2016
Galena Biopharma Inc at ROTH Conference Add to calendar
Mar 10, 2016
Q4 2015 Galena Biopharma Inc Earnings Call - 5:00PM EST - Add to calendar
Mar 10, 2016
Q4 2015 Galena Biopharma Inc Earnings Release - 4:00PM EST - Add to calendar
Feb 8, 2016
Galena Biopharma Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference - 11:30AM EST - Add to calendar
Jan 18, 2016
Galena Biopharma Inc at Noble Financial Capital Markets Equity Conference
Dec 8, 2015
Galena Biopharma Inc at Oppenheimer Healthcare Conference
Nov 9, 2015
Q3 2015 Galena Biopharma Inc Earnings Call - Webcast
Nov 9, 2015
Q3 2015 Galena Biopharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -392.81%
Operating margin - -558.56%
EBITD margin - -550.84%
Return on average assets -27.60% -43.46%
Return on average equity -62.31% -170.48%
Employees 57 -
CDP Score - -

Address

4640 SW Macadam Ave Ste 270
PORTLAND, OR 97239-4232
United States - Map
+1-855-8554253 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug, Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.

Officers and directors

Sanford J. Hillsberg J.D. Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Mark W. Schwartz Ph.D. President, Chief Executive Officer, Independent Director
Age: 58
Bio & Compensation  - Reuters
Bijan Nejadnik M.D. Executive Vice President and Chief Medical Officer
Bio & Compensation  - Reuters
Joseph Lasaga Vice President - Business Development
Bio & Compensation  - Reuters
William L. Ashton Independent Director
Age: 64
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Irving M. Einhorn Independent Director
Age: 72
Bio & Compensation  - Reuters
Stephen S. Galliker CPA Independent Director
Age: 67
Bio & Compensation  - Reuters
Steven A. Kriegsman Independent Director
Age: 73
Bio & Compensation  - Reuters